Concepedia

Dylan Conklin

DC

Statistics

Publications

14

Citations

2.6K

H-Index

13

Active since

2009

Affiliations

University of California, Los Angeles(Current)

Pfizer (United States)

University of Southern California

University of Pennsylvania

UCLA Jonsson Comprehensive Cancer Center

Dylan Conklin is an author at University of California, Los Angeles specializing in molecular oncology, oncology, and medicine.

ORCID

Publications per year

2009–2022

14

Publications

14

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Richard S. Finn, Judy Dering, Dylan Conklin et al. · Breast Cancer Research · 2009 · 1.4K citations · Full text

, , +17

Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays

Jun Li, Wei Zhao, Rehan Akbani et al. · Cancer Cell · 2017 · 236 citations · Full text

, , +13

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Neil A. O’Brien, Martina S.J. McDermott, Dylan Conklin et al. · Breast Cancer Research · 2020 · 156 citations · Full text

, , +16

Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis

Eric R. Welin, Aurapat Ngamnithiporn, Max Klatte et al. · Science · 2018 · 121 citations

, , +13

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

Neil A. O’Brien, K McDonald, Tong Luo et al. · Clinical Cancer Research · 2014 · 117 citations

, , +17

1–5 of 14